跳至主要内容
临床试验/CTRI/2025/06/088232
CTRI/2025/06/088232尚未招募不适用

Efficacy of Tranexamic acid spray on reduction of time taken for a complete cessation of Bleeding in acute Trauma patients

Shilpa Medicare Ltd.1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2025年6月15日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
100
试验地点
1
主要终点
To evaluate the safety and efficacy of the Tranexamic acid (TXA) spray 10% w/v with placebo (Placebo spray) on acute injury patients admitted to the ED.

研究概览

简要总结

Adequatehaemostasis after trauma and during surgical operation is a big challenge inmodern medicine. About the 40% traumatic and more than 90% of combat deathstook place in pre-hospital settings. And about the 50% from these deaths havebeen reported due to massive blood loss (1,2). The US FDA first approvedintravenous Tranexamic acid (TXA) in 1986 for short-term use as hemostaticagent. In 2009, FDA approved the Tranexamic acid (TXA) oral form (Tablets) forthe treatment of menorrhagia. Tranexamic acid -4-(aminomethyl)cyclohexane-1-carboxylic acid- is a synthetic amino acid lysine derivative thatcompetitively blocks the lysine binding sites on plasminogen (3,4).

IntravenousTranexamic acid is commonly used in severely bleeding patients and numberclinical trials were conducted. In 2010, CRASH-2 trial was a multi-centerrandomized, double-blinded, controlled trial where patients either receivedTranexamic acid or placebo in adult trauma patients with significanthemorrhage, tranexamic acid reduced all-cause mortality at 4 weeks and thedeath rate due to bleeding in trauma patients (5,6). The MATTERs trial followedthis in 2011 revealed TXA decreased overall mortality, notably those requiringmassive transfusion protocols (7). The off-label intravenous uses of Tranexamicacid are seen in surgical operations to reduce blood loss. Surgical operationslike total knee arthroplasty (8), orthognathic surgery (9), cardiac surgery(10) spinal surgeries, and transurethral retrograde prostatectomy (TURP,11).

Based onresults of clinical studies, oral Tranexamic acid was also used to reduce bloodloss in post-procedural after cervical conization (12) hereditary angioedema (13),transurethral retrograde prostatectomy (TURP) and tooth extractions in patientson oral anticoagulants (14). The research studies observed that Tranexamic acidis effective in reducing blood loss and transfusion without significant risksfor increased mortality, stroke, myocardial infarction, or renal failure (15,16,17).

In thiscontext, In the emergency and trauma setting, as bleeding control is animportant part, we are planning to investigate the use of tranexamic acidspray.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 45.00 Year(s)(—)
性别
All

入选标准

  • Adult more than 18 years acute trauma patients with isolated extremity wounds with active bleeding Time since injury.
  • less than 6 hours.

排除标准

  • Paediatric trauma patient age less than 18 yrs Patients with known Blood Coagulopathy Patients on anti-platelet and anti-fibrinolytics Patients suffering with Co-morbidities and pregnant women Patients with a history of hypersensitivity to tranexamic acid and any of the ingredients.

结局指标

主要结局

To evaluate the safety and efficacy of the Tranexamic acid (TXA) spray 10% w/v with placebo (Placebo spray) on acute injury patients admitted to the ED.

时间窗: Comparison and measurement of time to hemostasis at 1 min, 2 min 3 min, 5 min, 10 min, 15 min, 20min and 30 min.

次要结局

  • Comparison and measurement of time to hemostasis at 1 min, 2 min 3 min, 5 min, 10 min, 15 min, 20min and 30 min application of both test and placebo after tooth extraction to the respective groups.(Comparison and measurement of time to hemostasis at 1 min, 2 min 3 min, 5 min, 10 min, 15 min, 20min and 30 min.)

研究者

申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验